IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0035629.html
   My bibliography  Save this article

Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature

Author

Listed:
  • Yuan Su
  • Wei-Bing Yang
  • Shi Li
  • Zhi-Jian Ye
  • Huan-Zhong Shi
  • Qiong Zhou

Abstract

Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor which has been used in conjunction with other anti-cancer agents in the treatment of patients with many cancers. It remains controversial whether bevacizumab can prolong survival in cancer patients. This meta-analysis was therefore performed to evaluate effect of bevacizumab on survival in cancer patients. PubMed, EMBASE, and Web of Science databases were searched for English-language studies of randomized controlled trials comparing bevacizumab with control therapy published through February 8, 2012. Progression-free survival, overall survival, and one-year survival rate were analyzed using random- or fixed-effects model. Thirty one assessable randomized controlled trials were identified. A significant improvement in progression-free survival in cancer patients was attributable to bevacizumab compared with control therapy (hazard ratio, 0.72; 95% confidence interval, 0.68 to 0.76; p

Suggested Citation

  • Yuan Su & Wei-Bing Yang & Shi Li & Zhi-Jian Ye & Huan-Zhong Shi & Qiong Zhou, 2012. "Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature," PLOS ONE, Public Library of Science, vol. 7(4), pages 1-1, April.
    • Handle: RePEc:plo:pone00:0035629
    DOI: 10.1371/journal.pone.0035629
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035629
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0035629&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0035629?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Irena Ilic & Slobodan Jankovic & Milena Ilic, 2016. "Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-15, August.
    2. Huan Xia & Xiao-Juan Wang & Qiong Zhou & Huan-Zhong Shi & Zhao-Hui Tong, 2014. "Efficacy and Safety of Talc Pleurodesis for Malignant Pleural Effusion: A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-9, January.
    3. Xing-Lin Chen & Ying-Hong Lei & Cun-Fei Liu & Qun-Fang Yang & Pei-Yuan Zuo & Cheng-Yun Liu & Chang-Zhong Chen & Yu-Wei Liu, 2013. "Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis," PLOS ONE, Public Library of Science, vol. 8(6), pages 1-8, June.
    4. Fariba Ahmadizar & N Charlotte Onland-Moret & Anthonius de Boer & Geoffrey Liu & Anke H Maitland-van der Zee, 2015. "Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials," PLOS ONE, Public Library of Science, vol. 10(9), pages 1-27, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0035629. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.